Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuji Murakami

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Medical Oncology (Northwood, London, England)|April 29, 2019
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung diseaseRyota Shibaki, Shuji Murakami, Yuji Matsumoto, et al.
The Annals of Thoracic Surgery|June 27, 2016
Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung AdenocarcinomaTomoharu Yoshiya, Takahiro Mimae, Yasuhiro Tsutani, et al.
Lung Cancer (Amsterdam, Netherlands)|June 23, 2010
Correlations between thin-section CT findings, histopathological and clinical findings of small pulmonary adenocarcinomasHaruhiro Saito, Yoichi Kameda, Kazuo Masui, et al.
Cancer Science|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural MesotheliomaTakashi Kijima, Terufumi Kato, Yasushi Goto, et al.
European Journal of Radiology|October 23, 2010
Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findingsMizuki Ikehara, Haruhiro Saito, Tetsuro Kondo, et al.
Journal of Experimental Therapeutics & Oncology|January 13, 2011
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene statusFumihiro Oshita, Yohei Miyagi, Takeshi Honda, et al.
Japanese Journal of Clinical Oncology|August 28, 2016
Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinomaNorifumi Tsubokawa, Takahiro Mimae, Yoshihiro Miyata, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Clinical Lung Cancer|February 27, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasYusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, et al.
Thoracic Cancer|January 10, 2024
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma"Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Medical Oncology (Northwood, London, England)|April 29, 2019
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung diseaseRyota Shibaki, Shuji Murakami, Yuji Matsumoto, et al.
The Annals of Thoracic Surgery|June 27, 2016
Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung AdenocarcinomaTomoharu Yoshiya, Takahiro Mimae, Yasuhiro Tsutani, et al.
Lung Cancer (Amsterdam, Netherlands)|June 23, 2010
Correlations between thin-section CT findings, histopathological and clinical findings of small pulmonary adenocarcinomasHaruhiro Saito, Yoichi Kameda, Kazuo Masui, et al.
Cancer Science|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural MesotheliomaTakashi Kijima, Terufumi Kato, Yasushi Goto, et al.
European Journal of Radiology|October 23, 2010
Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findingsMizuki Ikehara, Haruhiro Saito, Tetsuro Kondo, et al.
Journal of Experimental Therapeutics & Oncology|January 13, 2011
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene statusFumihiro Oshita, Yohei Miyagi, Takeshi Honda, et al.
Japanese Journal of Clinical Oncology|August 28, 2016
Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinomaNorifumi Tsubokawa, Takahiro Mimae, Yoshihiro Miyata, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Clinical Lung Cancer|February 27, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasYusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, et al.
Thoracic Cancer|January 10, 2024
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma"Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, et al.
Pageof 12